培美曲塞联合调强放疗技术在Ⅲ期非小细胞肺癌治疗中的应用效果  

Application Effect of Pemetrexed Combined with Intensity Modulated Radiotherapy Technique in the Treatment of StageⅢNon-small Cell Lung Cancer

作　　者：黄凡[1] 彭肖龙 贺聪[1] HUANG Fan;PENG Xiaolong;HE Cong(Zhongxiang People's Hospital,Zhongxiang 429001,China;不详)

机构地区：[1]钟祥市人民医院,湖北钟祥429001

出　　处：《中外医学研究》2024年第20期127-130,共4页CHINESE AND FOREIGN MEDICAL RESEARCH

摘　　要：目的:探讨培美曲塞联合调强放疗技术(IMRt)在Ⅲ期非小细胞肺癌(NSCLC)治疗中的应用效果。方法:选取2021年1月—2022年8月钟祥市人民医院肿瘤内科收治的68例Ⅲ期非小细胞肺癌患者,按照随机数表法分为两组,各34例。培美曲塞组给予培美曲塞联合IMRt治疗,多西他赛组给予多西他赛联合IMRt治疗。比较两组患者临床疗效、生存率及不良反应。结果:治疗4个周期后,培美曲塞组客观缓解率、临床控制率与多西他赛组比较,差异均无统计学意义(P>0.05);培美曲塞组白细胞减少、恶心/呕吐、脱发发生率均明显低于多西他赛组,差异有统计学意义(P<0.05);两组疾病进展时间及1年生存率比较,差异无统计学意义(P>0.05)。结论:培美曲塞联合IMRt与多西他赛联合IMRt治疗Ⅲ期NSCLC的效果相当,但培美曲塞的不良反应发生率低。Objective:To explore the application effect of Pemetrexed combined with Intensity modulated radiotherapy technique(IMRt)in the treatment of stageⅢnon-small cell lung cancer(NSCLC).Method:A total of 68 patients with stageⅢnon-small cell lung cancer were randomly admitted to the Department of Oncology of Zhongxiang People's Hospital from January 2021 to August 2022 were selected.The patients were divided into two groups by random number table method,34 cases in each group.The Pemetrexed group was treated with Pemetrexed combined with IMRt,while the Docetaxel group was treated with Docetaxel combined with IMRt.The clinical efficacy,survival rate,and adverse reactions between the two groups were compared between the two groups.Result:After 4 cycles of treatment,there were no significant differences in objective remission rate and clinical control rate between Pemetrexed group and Docetaxel group(P>0.05).The incidences of leukopenia,nausea/vomiting,and hair loss in the Pemetrexed group were significantly lower than those in the Docetaxel group,and the differences were statistically significant(P<0.05).There were no significant differences in disease progression and the 1 year survival rate between the two groups(P>0.05).Conclusion:The efficacy of Pemetrexed chemotherapy combined with IMRt and Docetaxel with IMRt in the treatment of stageⅢNSCLC is comparable.However,the incidence of adverse reactions with Pemetrexed is low,which deserves clinical attention.

关 键 词：非小细胞肺癌 三维适形放射治疗 培美曲塞 多西他赛 应用效果 

分 类 号：R734.2[医药卫生—肿瘤]